Le Lézard
Classified in: Health, Science and technology
Subject: PDT

KT to Build Digital Healthcare System on Trans-Siberian Trains


SEOUL, South Korea, May 24, 2018 /PRNewswire/ -- KT Corp. (KRX: 03200; NYSE: KT) announced today that it will install a telemedicine system on the trans-Siberian railway and facilitate digital healthcare solutions by connecting hospitals affiliated with the state-owned Russian Railways.

The pilot plan is part of the ICT-based Medical System Expansion Project spearheaded by the Korea Health Industry Development Institute, an agency of the Ministry of Health and Welfare. KT, South Korea's leading telephone and Internet provider, also participated in the project in 2017, constructing a digital healthcare platform and solution for 12 hospitals in Kazakhstan.

KT and Russian Railways signed an agreement in December 2017 to jointly create a mobile diagnostics solution for primary care at hospitals in Russian rail stations as well as on trans-Siberian trains. Russian Railways, one of the world's three largest rail transportation companies, manages 173 hospitals across Russia.

Under the agreement, KT will work with the Seoul National University Bundang Hospital to set up a telemedicine system for six hospitals, one in Moscow and five in various regions, by June. KT will supply a digital healthcare solution, and the SNU hospital will offer diagnostic advice to Korean and Russian medical staffs and assist in personnel training. The telemedicine system for trans-Siberian trains will be maintained until the end of this year.

KT's Digital Healthcare Solution and Platform won the Award for Best Mobile Innovation for Health at the Mobile World Congress 2018, held in February, in Barcelona, Spain.

The trans-Siberian railway, operated by Russian Railways, connects Moscow and Vladivostok. A one-way trip takes seven days. Currently, the trans-Siberian trains only have basic diagnostic devices such as thermometers and blood pressure monitors. Therefore, it is difficult to check the condition of passengers who should be monitored closely such as pregnant women and heart patients or realize a passenger has an internal organ problem that requires urgent treatment.

KT plans to install its digital healthcare solution devices on the trains. They will enable rapid diagnosis with a small amount of blood and urine on such cardiovascular diseases as angina and myocardial infarction, as well as respiratory diseases, diabetes and prostate cancer. The solution also provides ultrasonography to diagnose kidneys, liver and gallbladder, fetal sonography, and basic blood and musculoskeletal system tests.

Media Contacts

Please contact us at [email protected] or visit our English website at https://corp.kt.com/eng/


These press releases may also interest you

at 23:14
As the graduation season approaches, COOFANDY, the modern men's essentials designer, is rolling out the red carpet for graduates with its "Style for Celebrations" theme. The brand encourages participants to share their graduation highlights using...

at 23:05
AI is the CIO's top priority, according to findings of Lenovo's third annual global CIO report. Inside the Tornado: How AI is Reshaping Corporate IT Today, reveals that while CIOs need to adopt and scale AI urgently, their ambitions are threatened by...

at 23:00
OPUS, the opportunity community for business builders, today announces a partnership with leading Dubai-based think-tank, Fiker Institute, as it launches in the...

at 23:00
Amkan Ventures, officially launched today and is announcing a $10M Fund of Funds (FoF) dedicated to backing emerging venture managers in the US. The new FoF is building a portfolio of a dozen funds across tech-enabled industries. Amkan Ventures...

at 22:33
The report titled "Building Energy Management Systems Market by Component (Hardware, Services, Software), Type (Integrated Building Energy Management Systems, Standalone Building Energy Management Systems), Application, Deployment Mode, End-Use -...

at 22:15
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...



News published on and distributed by: